• Je něco špatně v tomto záznamu ?

Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic

R. Aiglova, M. Taborsky, M. Lazarova, L. Pavlu, J. Danek, J. Precek, A. Schee, V. Gloger, V. Cernicek, M. Vicha, T. Skala

. 2022 ; 166 (3) : 322-327. [pub] 20210604

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22022915

AIMS: Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at angiotensin-converting enzyme inhibitors (ACEI), angiotensin-II-receptor antagonists (ARB) and angiotensin receptor blocker/neprilysin inhibitor (ARNI) use. METHODS AND RESULTS: ACEi and ARBs were generally used in 87.6% of all HF patients in 2012 (n=154 627); 84.5% in 2013 (n=170 861); 83.5% in 2014 (n=186 963); 81.6% in 2015 (n=198 844); 80.1% in 2016 (n=205 793); 78.0% in 2017 (n=212 152) and in 76.7% in 2018 (n=219 235). In a sub-analysis of patients with a medical procedure and/or examination using an I50.x ICD code accounted for in the given year, ACEi and ARBs were generally used in 99.3% in 2012 (n=63 250); 96% in 2013 (n=62 241); 95.2% in 2014 (n=64 414); 93.3% in 2015 (n=65 217); 91.8% in 2016 (n=65 236); 90.1% in 2017 (n=65 761) and in 88.6% in 2018 (n=66 332). In 2018, the majority of patients with HF were prescribed ramipril (n=49 909; 17.5%) and perindopril (n=44 332; 15.5%). The mostly prescribed ARBs in 2018 were telmisartan (n=18 669; 6.5%); losartan (n=13 935; 4.9%) and valsartan (n=4 849; 1.7%). In 24.5% of cases, ACEIs and ARBs were prescribed in a fixed combination with another drug. ARNI became gradually more prescribed from 2018 (n=9 659 in November 2020). CONCLUSION: In an analysis of ACEIs, ARBs and ARNIs utilization in all patients treated for heart failure in the given year in the whole country, we found a comparable rate of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Ramipril and perindopril remained the mostly prescribed ACEIs and telmisartan became the mostly prescribed ARB. Since 2018, ARNIs began to be widely prescribed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22022915
003      
CZ-PrNML
005      
20230118155259.0
007      
ta
008      
221007s2022 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2021.035 $2 doi
035    __
$a (PubMed)34092792
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Aiglová, Renáta $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0227652
245    10
$a Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic / $c R. Aiglova, M. Taborsky, M. Lazarova, L. Pavlu, J. Danek, J. Precek, A. Schee, V. Gloger, V. Cernicek, M. Vicha, T. Skala
520    9_
$a AIMS: Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at angiotensin-converting enzyme inhibitors (ACEI), angiotensin-II-receptor antagonists (ARB) and angiotensin receptor blocker/neprilysin inhibitor (ARNI) use. METHODS AND RESULTS: ACEi and ARBs were generally used in 87.6% of all HF patients in 2012 (n=154 627); 84.5% in 2013 (n=170 861); 83.5% in 2014 (n=186 963); 81.6% in 2015 (n=198 844); 80.1% in 2016 (n=205 793); 78.0% in 2017 (n=212 152) and in 76.7% in 2018 (n=219 235). In a sub-analysis of patients with a medical procedure and/or examination using an I50.x ICD code accounted for in the given year, ACEi and ARBs were generally used in 99.3% in 2012 (n=63 250); 96% in 2013 (n=62 241); 95.2% in 2014 (n=64 414); 93.3% in 2015 (n=65 217); 91.8% in 2016 (n=65 236); 90.1% in 2017 (n=65 761) and in 88.6% in 2018 (n=66 332). In 2018, the majority of patients with HF were prescribed ramipril (n=49 909; 17.5%) and perindopril (n=44 332; 15.5%). The mostly prescribed ARBs in 2018 were telmisartan (n=18 669; 6.5%); losartan (n=13 935; 4.9%) and valsartan (n=4 849; 1.7%). In 24.5% of cases, ACEIs and ARBs were prescribed in a fixed combination with another drug. ARNI became gradually more prescribed from 2018 (n=9 659 in November 2020). CONCLUSION: In an analysis of ACEIs, ARBs and ARNIs utilization in all patients treated for heart failure in the given year in the whole country, we found a comparable rate of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Ramipril and perindopril remained the mostly prescribed ACEIs and telmisartan became the mostly prescribed ARB. Since 2018, ARNIs began to be widely prescribed.
650    _2
$a receptor typu 2 angiotensinu II - blokátory $x terapeutické užití $7 D057912
650    12
$a antagonisté receptorů pro angiotenzin $x terapeutické užití $7 D057911
650    _2
$a inhibitory ACE $x terapeutické užití $7 D000806
650    _2
$a angiotensiny $x terapeutické užití $7 D000809
650    _2
$a antihypertenziva $7 D000959
650    12
$a srdeční selhání $x farmakoterapie $x epidemiologie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a losartan $x terapeutické užití $7 D019808
650    _2
$a neprilysin $x terapeutické užití $7 D015260
650    _2
$a perindopril $x terapeutické užití $7 D020913
650    _2
$a ramipril $x terapeutické užití $7 D017257
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a telmisartan $x terapeutické užití $7 D000077333
650    _2
$a valsartan $x terapeutické užití $7 D000068756
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Táborský, Miloš, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $d 1962- $7 jn20010310074
700    1_
$a Lazárová, Marie $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0074090
700    1_
$a Pavlů, Luděk $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0236019
700    1_
$a Daněk, Josef $u Department of Internal Medicine, Military University Hospital Prague, Prague, Czech Republic $7 xx0242063
700    1_
$a Přeček, Jan, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $d 1985- $7 xx0154445
700    1_
$a Schee, Alexandr $u Cardio center, Regional Hospital Karlovy Vary, Karlovy Vary, Czech Republic $7 xx0134780
700    1_
$a Gloger, Vít $u Bata's Regional Hospital, Zlin, Czech Republic $7 xx0209738
700    1_
$a Černíček, Vlastimil $u Bata's Regional Hospital, Zlin, Czech Republic $7 xx0244011
700    1_
$a Vícha, Marek $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0229304
700    1_
$a Skála, Tomáš $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0137536
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 166, č. 3 (2022), s. 322-327
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34092792 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20221007 $b ABA008
991    __
$a 20230118155253 $b ABA008
999    __
$a ok $b bmc $g 1885621 $s 1174201
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 166 $c 3 $d 322-327 $e 20210604 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK138 $a Pubmed-20221007

Najít záznam

Citační ukazatele

Možnosti archivace